DE3346237A1 - Verwendung von buspiron oder eines pharmazeutisch vertraeglichen saeureadditionssalzes davon zur behandlung extrapyramidaler motorischer stoerungen - Google Patents
Verwendung von buspiron oder eines pharmazeutisch vertraeglichen saeureadditionssalzes davon zur behandlung extrapyramidaler motorischer stoerungenInfo
- Publication number
- DE3346237A1 DE3346237A1 DE19833346237 DE3346237A DE3346237A1 DE 3346237 A1 DE3346237 A1 DE 3346237A1 DE 19833346237 DE19833346237 DE 19833346237 DE 3346237 A DE3346237 A DE 3346237A DE 3346237 A1 DE3346237 A1 DE 3346237A1
- Authority
- DE
- Germany
- Prior art keywords
- buspirone
- motor disorders
- acid addition
- extrapyramidal
- extrapyramidal motor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000019430 Motor disease Diseases 0.000 title claims description 14
- 239000002253 acid Substances 0.000 title claims description 9
- 150000003839 salts Chemical class 0.000 title claims description 8
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 claims description 26
- 229960002495 buspirone Drugs 0.000 claims description 21
- 208000027776 Extrapyramidal disease Diseases 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 12
- 239000003176 neuroleptic agent Substances 0.000 claims description 7
- 230000000701 neuroleptic effect Effects 0.000 claims description 6
- 208000027089 Parkinsonian disease Diseases 0.000 claims description 5
- 206010034010 Parkinsonism Diseases 0.000 claims description 5
- 229960001768 buspirone hydrochloride Drugs 0.000 claims description 5
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 230000003000 nontoxic effect Effects 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 241001465754 Metazoa Species 0.000 description 21
- 208000009132 Catalepsy Diseases 0.000 description 18
- 206010047853 Waxy flexibility Diseases 0.000 description 18
- 229940079593 drug Drugs 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 241000700159 Rattus Species 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000036544 posture Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 4
- ZEWQUBUPAILYHI-UHFFFAOYSA-N trifluoperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 ZEWQUBUPAILYHI-UHFFFAOYSA-N 0.000 description 4
- 229960002324 trifluoperazine Drugs 0.000 description 4
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 3
- 206010001541 Akinesia Diseases 0.000 description 3
- 208000012902 Nervous system disease Diseases 0.000 description 3
- 208000025966 Neurological disease Diseases 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 229960003638 dopamine Drugs 0.000 description 3
- 229950000688 phenothiazine Drugs 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 230000001078 anti-cholinergic effect Effects 0.000 description 2
- 230000002903 catalepsic effect Effects 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- MHCVCKDNQYMGEX-UHFFFAOYSA-N 1,1'-biphenyl;phenoxybenzene Chemical group C1=CC=CC=C1C1=CC=CC=C1.C=1C=CC=CC=1OC1=CC=CC=C1 MHCVCKDNQYMGEX-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- 208000012639 Balance disease Diseases 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 208000014094 Dystonic disease Diseases 0.000 description 1
- 208000019468 Iatrogenic Disease Diseases 0.000 description 1
- 206010021703 Indifference Diseases 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- 208000002740 Muscle Rigidity Diseases 0.000 description 1
- 206010028347 Muscle twitching Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 1
- 229910001573 adamantine Inorganic materials 0.000 description 1
- 230000003270 anti-cataleptic effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 208000018300 basal ganglia disease Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
- 229960002802 bromocriptine Drugs 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 206010007776 catatonia Diseases 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000000534 dopa decarboxylase inhibitor Substances 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001003 psychopharmacologic effect Effects 0.000 description 1
- 230000000506 psychotropic effect Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/452,686 US4438119A (en) | 1982-12-23 | 1982-12-23 | Method for alleviation of extrapyramidal motor disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE3346237A1 true DE3346237A1 (de) | 1984-07-05 |
Family
ID=23797489
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19833346237 Withdrawn DE3346237A1 (de) | 1982-12-23 | 1983-12-21 | Verwendung von buspiron oder eines pharmazeutisch vertraeglichen saeureadditionssalzes davon zur behandlung extrapyramidaler motorischer stoerungen |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US4438119A (cg-RX-API-DMAC7.html) |
| JP (1) | JPS59130215A (cg-RX-API-DMAC7.html) |
| AU (1) | AU556112B2 (cg-RX-API-DMAC7.html) |
| BE (1) | BE898540A (cg-RX-API-DMAC7.html) |
| DE (1) | DE3346237A1 (cg-RX-API-DMAC7.html) |
| PH (1) | PH18968A (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA839451B (cg-RX-API-DMAC7.html) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4634703A (en) * | 1985-10-25 | 1987-01-06 | Bristol-Myers Company | Method for alleviation of panic disorders |
| US4640921A (en) * | 1986-02-04 | 1987-02-03 | Bristol-Myers | Treatment of sexual dysfunction with buspirone |
| US4687772A (en) * | 1986-10-07 | 1987-08-18 | Bristol-Myers Company | Method for improvement of short term memory |
| US4777173A (en) * | 1987-03-25 | 1988-10-11 | Bristol-Myers Company | Method for treatment of alcohol abuse |
| DE3736974A1 (de) * | 1987-10-31 | 1989-05-11 | Troponwerke Gmbh & Co Kg | Verwendung von 2-pyrimidinyl-1-piperazin-derivaten |
| US5468749A (en) * | 1988-08-30 | 1995-11-21 | Gawin; Frank H. | Method for treatment of substance addiction |
| US6432956B1 (en) | 1990-02-12 | 2002-08-13 | William C. Dement | Method for treatment of sleep apneas |
| US5633009A (en) * | 1990-11-28 | 1997-05-27 | Sano Corporation | Transdermal administration of azapirones |
| US5824680A (en) * | 1991-08-31 | 1998-10-20 | Bayer Aktiengesellschaft | Ipsapirone for the treatment of alzheimer's disease by improving memory |
| US5631017A (en) * | 1993-03-26 | 1997-05-20 | Beth Israel Deaconess Medical Center, Inc. | Topical application of buspirone for treatment of pathological conditions associated with immune responses |
| US5484788A (en) * | 1993-03-26 | 1996-01-16 | Beth Israel Hospital Association | Buspirone as a systemic immunosuppressant |
| US5637314A (en) * | 1995-06-07 | 1997-06-10 | Beth Israel Deaconess Medical Center, Inc. | Topical and systemic application of buspirone or derivatives thereof for treating atopic dermatitis |
| UA73981C2 (en) * | 2000-03-10 | 2005-10-17 | Merck Patent Gmbh | (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane for treatment of extrapyramidal movement disorders (variants), pharmaceutical composition and kit |
| US7053092B2 (en) | 2001-01-29 | 2006-05-30 | Otsuka Pharmaceutical Co., Ltd. | 5-HT1a receptor subtype agonist |
| AU2002355170B2 (en) * | 2001-07-26 | 2007-06-07 | Merck Patent Gmbh | Novel use of 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts |
| AR033485A1 (es) | 2001-09-25 | 2003-12-26 | Otsuka Pharma Co Ltd | Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma |
| TW200800306A (en) * | 2005-09-12 | 2008-01-01 | Wyeth Corp | Sustained-release formulation and uses thereof |
| GT200600416A (es) * | 2005-09-12 | 2007-09-20 | Sales salicilato y gentisato de un compuesto de piperazina | |
| GT200600414A (es) * | 2005-09-12 | 2007-09-20 | Sal de glucuranato de compuesto de piperazine | |
| CA2813648C (en) * | 2010-10-15 | 2019-06-25 | Concit Pharma Aps | Combinations of serotonin receptor agonists for treatment of movement disorders |
| CA2870123C (en) | 2012-04-18 | 2021-02-23 | Contera Pharma Aps | Orally available pharmaceutical formulation suitable for improved management of movement disorders |
| KR102527805B1 (ko) * | 2014-06-26 | 2023-04-28 | 콘테라 파르마 에이/에스 | 부스피론 대사물의 용도 |
| KR102443161B1 (ko) | 2016-07-11 | 2022-09-14 | 콘테라 파르마 에이/에스 | 아침 운동 불능을 치료하기 위한 박동성 약물 전달 시스템 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4182763A (en) * | 1978-05-22 | 1980-01-08 | Mead Johnson & Company | Buspirone anti-anxiety method |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE759371A (fr) | 1969-11-24 | 1971-05-24 | Bristol Myers Co | Azaspirodecanediones heterocycliques et procedes pour leur preparation |
| US3976776A (en) | 1972-12-06 | 1976-08-24 | Mead Johnson & Company | Tranquilizer process employing N-(heteroarcyclic)piperazinylalkylazaspiroalkanediones |
-
1982
- 1982-12-23 US US06/452,686 patent/US4438119A/en not_active Expired - Lifetime
-
1983
- 1983-12-20 ZA ZA839451A patent/ZA839451B/xx unknown
- 1983-12-21 DE DE19833346237 patent/DE3346237A1/de not_active Withdrawn
- 1983-12-22 AU AU22793/83A patent/AU556112B2/en not_active Expired
- 1983-12-22 BE BE0/212106A patent/BE898540A/fr not_active IP Right Cessation
- 1983-12-23 JP JP58242302A patent/JPS59130215A/ja active Granted
- 1983-12-23 PH PH30027A patent/PH18968A/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4182763A (en) * | 1978-05-22 | 1980-01-08 | Mead Johnson & Company | Buspirone anti-anxiety method |
Non-Patent Citations (3)
| Title |
|---|
| CLINIC * |
| CLINIC J.: Psychiatry 43(12), 1982, S. 11-18 |
| J.: Psychiatry 43(12), 1982, S. 11-18 * |
Also Published As
| Publication number | Publication date |
|---|---|
| ZA839451B (en) | 1984-09-26 |
| BE898540A (fr) | 1984-06-22 |
| AU2279383A (en) | 1984-06-28 |
| JPH0422889B2 (cg-RX-API-DMAC7.html) | 1992-04-20 |
| JPS59130215A (ja) | 1984-07-26 |
| PH18968A (en) | 1985-11-26 |
| AU556112B2 (en) | 1986-10-23 |
| US4438119A (en) | 1984-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3346237A1 (de) | Verwendung von buspiron oder eines pharmazeutisch vertraeglichen saeureadditionssalzes davon zur behandlung extrapyramidaler motorischer stoerungen | |
| DE60103556T3 (de) | Zusammensetzungen zur behandlung von fettleibigkeit, welche antagonisten der cb1-rezeptoren und sibutramine enthalten | |
| DE69028542T2 (de) | Felbamat zur Behandlung der Lennox-Gastaut syndrome | |
| DE2920739C2 (cg-RX-API-DMAC7.html) | ||
| DE3876877T2 (de) | Verwendung von indolon-derivaten zur herstellung von arzneimitteln zur behandlung des parkinsonismus. | |
| DE60122368T2 (de) | Verwendung von Gaboxadol zur Behandlung von premenstruelle Störung, postnatal Depression oder postmenopausal-bedingte-dysphorische Störung | |
| DE3688038T2 (de) | Verwendung von buspiron zur herstellung von pharmazeutischen zusammensetzungen zur linderung von krankhaften angst. | |
| DE3780618T2 (de) | Verwendung von buspiron zur verbesserung des kurzzeitgedaechtnisses. | |
| DE60218193T2 (de) | Verwendung von 2-oxo-1-pyrrolidin-derivaten zur herstellung eines arzneimittels zur behandlung von dyskinesia | |
| DE60101309T2 (de) | Diacerein zur behandlung von psoriasis | |
| DE69725879T2 (de) | VERWENDUNG VON p-AMINOPHENOLDERIVATEN ZUR HERSTELLUNG VON PHARMAZEUTISCHEN ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON NEURODEGENERATIVEN ERKRANKUNGEN | |
| DE3390114T1 (de) | Verbesserte analgetische und antiinflammatorische, Ibuprofen enthaltende Zubereitungen und Verfahren zu ihrer Herstellung | |
| DE69333413T2 (de) | 5-ht2-antagonisten in der behandlung venöser zustände | |
| DE3850154T2 (de) | Verwendung von Gepiron zur Herstellung eines pharmazeutischen Präparats zur Behandlung atypischer Depression. | |
| DE3715378A1 (de) | Arzneimittelkombination zur prophylaxe und therapie von malaria | |
| DE69131398T2 (de) | Verwendung von 5-ht4 rezeptorantagonisten zur behandlung von vorhof-fibrillation und zur vorbeugung von schlaganfall | |
| EP1513533B1 (de) | Pharmazeutische wirkstoffkombination sowie deren verwendung | |
| DE60015098T2 (de) | 3-cyclopropylmethoxy-4-difluormethoxy-n-(3,5-dichlor-pyrid-4-yl)-benzamid zur behandlung von multipler sklerose | |
| DE68907392T2 (de) | Dysmnesie modifizierende Arzneimittel. | |
| EP1152762A1 (de) | Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz | |
| DE69907387T2 (de) | Verwendung von Hydantoin-Derivaten zur Herstellung eines Medikaments zur Behandlung von refraktärer Vasculitis. | |
| DE69127285T2 (de) | Verwendung von verbindungen zur behandlung von altersbedingtem gedächtnisschwund und anderen kognitiven störungen | |
| DE60034249T2 (de) | Kombination enthaltend cyamemazine und ein atypisches neuroleptikum | |
| DE3782651T2 (de) | Anwendung von n-(2-(diaethylamino)aethyl)-2-methoxy-4((1-h-4,5-dihydro-2-imidazolyl)amino)-5-chlorobenzamid als anxiolytisches und antipsychotisches mittel. | |
| DE2720194A1 (de) | Verwendung von trazodon und etoperidon zum behandeln des parkinson-tremors und anderer extra- pyramidaler syndrome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8127 | New person/name/address of the applicant |
Owner name: BRISTOL-MYERS SQUIBB CO. (N.D.GES.D.STAATES DELAWA |
|
| 8128 | New person/name/address of the agent |
Representative=s name: KINZEBACH, W., DIPL.-CHEM. DR.PHIL. RIEDL, P., DIP |
|
| 8110 | Request for examination paragraph 44 | ||
| 8130 | Withdrawal |